Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | American Journal of Hypertension |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1093/ajh/hpt201 |
| Field | Physiology |
| Keywords | NO donors; VEGF.; angiogenesis inhibitors; blood pressure; hypertension; nitric oxide (NO) |
| Description | Hypertension is the most common adverse effect of the inhibitors of vascular endothelial growth factor (VEGF) pathwaybased therapy (VEGF pathway inhibitors therapy, VPI therapy) in cancer patients. VPI includes monoclonal antibodies against VEGF, tyrosine kinase inhibitors, VEGF Traps, and so-called aptamers that may become clinically relevant in the future. All of these substances inhibit the VEGF pathway, which in turn causes a decrease in nitric oxide (NO) and an increase in blood pressure, with the consequent development of hypertension and its final events (e.g., myocardial infarction or stroke). To our knowledge, there is no current study on how to provide an optimal therapy for patients on VPI therapy with hypertension. This review summarizes the roles of VEGF and NO in vessel biology, provides an overview of VPI agents, and suggests a potential treatment procedure for patients with VPI-induced hypertension. |